Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17654017 | 0.77 | — | — | |
| SCHEMBL15160718 | 0.72 | TRPA1 (0.40) | TRPA1ALDH1A1 | |
| SCHEMBL19336228 | 0.70 | ALDH1A1 (0.42) | TRPA1ALDH1A1 | |
| SCHEMBL20897220 | 0.70 | TRPA1 (0.39) | TRPA1ALDH1A1 | |
| SCHEMBL14141193 | 0.68 | ALDH1A1 (0.32) | ALDH1A1 | |
| SCHEMBL11168286 | 0.67 | ACVR1 (0.41) | — | |
| SCHEMBL20169555 | 0.67 | TRPA1 (0.37) | TRPA1ALDH1A1 | |
| SCHEMBL4591696 | 0.67 | GSK3A (0.43) | — | |
| SCHEMBL1872402 | 0.65 | TRPA1 (0.54) | TRPA1ALDH1A1 | |
| SCHEMBL6054987 | 0.64 | TRPA1 (0.35) | TRPA1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0474595-B1 | Aqueous dispersion of low-solubility UV-absorbers | CIBA GEIGY AG (CH) | 1995-09-27 | — | — | EP | claimed |
| EP-4722209-A1 | PROTAC COMPOUND TARGETING ESTROGEN RECEPTOR, PREPARATION METHOD THEREFOR, AND USE THEREOF | Beijing Shenogen Pharma Group (CN) | 2026-04-08 | — | — | EP | disclosed |
| WO-2025026283-A1 | COMPOUND FOR SELECTIVELY DEGRADING SMARCA2/4 AND USE THEREOF | 甘李药业股份有限公司 | 2025-02-06 | — | — | WO | disclosed |
| WO-2024156294-A1 | ESTROGEN RECEPTOR PROTEOLYSIS TARGETING CHIMERA COMPOUND AND USE THEREOF | 甘李药业股份有限公司 | 2024-08-02 | — | — | WO | disclosed |
| CN-118201929-A | PROTAC compound, pharmaceutical composition containing same, and preparation method and application thereof | 广东弘烨医药科技有限公司 | 2024-06-14 | — | — | CN | disclosed |
| WO-2024017372-A1 | INDOLONE DERIVATIVE AND USE THEREOF | 成都百裕制药股份有限公司 | 2024-01-25 | — | — | WO | disclosed |
| US-20230357249-A1 | ANDROGEN RECEPTOR PROTEIN DEGRADERS WITH A TRICYCLIC CEREBLON LIGAND | UNIV MICHIGAN REGENTS (US) | 2023-11-09 | — | — | US | disclosed |
| WO-2023072270-A1 | PROTAC COMPOUND, PHARMACEUTICAL COMPOSITION COMPRISING SAME, PREPARATION METHOD THEREFOR, AND USE THEREOF | 百极弘烨(南通)医药科技有限公司 | 2023-05-04 | — | — | WO | disclosed |
| US-20220388978-A1 | CEREBLON E3 LIGASE INHIBITORS | REGENTS OF THE UNIVERSITY OF MICHIGAN | 2022-12-08 | — | — | US | disclosed |
| CN-115023267-A | Spirocyclic androgen receptor protein degrading agents | 密歇根大学董事会 | 2022-09-06 | — | — | CN | disclosed |
| CN-114641337-A | CEREBLON E3 ligase inhibitors | 密歇根大学董事会 | 2022-06-17 | — | — | CN | disclosed |
| EP-3359544-B1 | NOVEL MODIFIED MACROCYCLIC COMPOUNDS | Bayer Pharma AG (DE) | 2020-08-12 | — | — | EP | disclosed |
| WO-2017060167-A1 | NOVEL MODIFIED MACROCYCLIC COMPOUNDS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-04-13 | — | — | WO | disclosed |
| US-9594187-B2 | Material for optical film, polymer, article prepared by using the polymer, and display device including the article | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2017-03-14 | — | — | US | disclosed |
| EP-2689031-B1 | FUNCTIONALIZED 3-ALKYNYL PYRAZOLOPYRIMIDINE ANALOGUES AS UNIVERSAL BASES AND METHODS OF USE | ELITECHGROUP B V (NL) | 2016-10-19 | — | — | EP | disclosed |
| US-20130303691-A1 | NOVEL MATERIAL FOR OPTICAL FILM, POLYMER, ARTICLE PREPARED BY USING THE POLYMER, AND DISPLAY DEVICE INCLUDING THE ARTICLE | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2013-11-14 | — | — | US | disclosed |
| US-8476411-B2 | Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides | AMBRX, INC. (US) | 2013-07-02 | — | — | US | disclosed |
| WO-2013033476-A1 | BRANCHED DISCRETTE PEG CONSTRUCTS | QUANTA BIODESIGN, LTD. (US) | 2013-03-07 | — | — | WO | disclosed |
| US-20090123968-A1 | Compositions Containing, Methods Involving, and Uses of Non-Natural Amino Acids and Polypeptides | AMBRX, INC. (US) | 2009-05-14 | — | — | US | disclosed |
| WO-2008024337-A2 | COMPOUNDS AND METHODS FOR INHIBITING THE INTERACTION OF BCL PROTEINS WITH BINDING PARTNERS | INFINITY DISCOVERY, INC. (US) | 2008-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090123968-A1 | Compositions Containing, Methods Involving, and Uses of Non-Natural Amino Acids and Polypeptides | PTMS, DAO, DNPEP | TRPA1 4774/4885ALDH1A1 3172/4885 |
| US-20230357249-A1 | ANDROGEN RECEPTOR PROTEIN DEGRADERS WITH A TRICYCLIC CEREBLON LIGAND | AR, GPER1, CRBN | TRPA1 2349/4885ALDH1A1 291/4885 |
| US-20220388978-A1 | CEREBLON E3 LIGASE INHIBITORS | CRBN, CUL3, UBE3A | TRPA1 4828/4885ALDH1A1 3487/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.